Field Evaluation of a Pan-Lassa Rapid Diagnostic Test During the 2018 Nigerian Lassa Fever Outbreak

Lassa virus (LASV) is the causative agent of Lassa fever (LF), an often-fatal hemorrhagic disease. LF is endemic in Nigeria, Sierra Leone and other West African countries. Diagnosis of LASV infection is challenged by the genetic diversity of the virus, which is greatest in Nigeria. The ReLASV Pan-Lassa Antigen Rapid Test (Pan-Lassa RDT) is a point-of-care, in vitro diagnostic test that utilizes a mixture of polyclonal antibodies raised against recombinant nucleoproteins of representative strains from the three most prevalent LASV lineages (II, III and IV). We compared the performance of the Pan-LASV RDT to available quantitative PCR (qPCR) assays during the 2018 LF outbreak in Nigeria. For patients with acute LF (RDT positive, IgG/IgM negative) during initial screening, RDT performance was 83.3% sensitivity and 92.8% specificity when compared to composite results of two qPCR assays. 100% of samples that gave Ct values below 22 on both qPCR assays were positive on the Pan-Lassa RDT. There were significantly elevated case fatality rates and elevated liver transaminase levels in subjects whose samples were RDT positive compared to RDT negative.

Citing Articles

Lassa Fever: Critical Review and Prospects for Control.

Besson M, Pepin M, Metral P Trop Med Infect Dis. 2024; 9(8).

PMID: 39195616 PMC: 11359316. DOI: 10.3390/tropicalmed9080178.

The Perspectives of Healthcare Professionals on the Strategies, Challenges, and Community Responses to Health System Response and Interventions Towards Lassa Fever Infections and Mortality in Sierra Leone.

Kamara A, Fatoma P, Moseray A Risk Manag Healthc Policy. 2024; 17:1127-1149.

PMID: 38737418 PMC: 11088388. DOI: 10.2147/RMHP.S455254.

The Arenaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens.

Hastie K, Melnik L, Cross R, Klitting R, Andersen K, Saphire E J Infect Dis. 2023; 228(Suppl 6):S359-S375.

PMID: 37849403 PMC: 10582522. DOI: 10.1093/infdis/jiac266.

Lassa Fever Natural History and Clinical Management.

Grant D, Samuels R, Garry R, Schieffelin J Curr Top Microbiol Immunol. 2023; 440:165-192.

PMID: 37106159 DOI: 10.1007/82_2023_263.

Beyond Lassa Fever: Systemic and structural barriers to disease detection and response in Sierra Leone.

Rohan H PLoS Negl Trop Dis. 2022; 16(5):e0010423.

PMID: 35587495 PMC: 9159599. DOI: 10.1371/journal.pntd.0010423.

References

de La Vega M, Caleo G, Audet J, Qiu X, Kozak R, Brooks J . Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest. 2015; 125(12):4421-8. PMC: 4665775. DOI: 10.1172/JCI83162. View

Trombley A, Wachter L, Garrison J, Buckley-Beason V, Jahrling J, Hensley L . Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg. 2010; 82(5):954-60. PMC: 2861391. DOI: 10.4269/ajtmh.2010.09-0636. View

Whitmer S, Strecker T, Cadar D, Dienes H, Faber K, Patel K . New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis. 2018; 24(3):599-602. PMC: 5823357. DOI: 10.3201/eid2403.171905. View

Plotkin S . Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother. 2017; 13(12):2755-2762. PMC: 5718831. DOI: 10.1080/21645515.2017.1306615. View

Lin W, Kouyos R, Adams R, Grenfell B, Griffin D . Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A. 2012; 109(37):14989-94. PMC: 3443140. DOI: 10.1073/pnas.1211138109. View

Emperador D, Yimer S, Mazzola L, Norheim G, Kelly-Cirino C . Diagnostic applications for Lassa fever in limited-resource settings. BMJ Glob Health. 2019; 4(Suppl 2):e001119. PMC: 6407552. DOI: 10.1136/bmjgh-2018-001119. View

Branco L, Matschiner A, Fair J, Goba A, Sampey D, Ferro P . Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J. 2008; 5:74. PMC: 2435526. DOI: 10.1186/1743-422X-5-74. View

Robinson J, Hastie K, Cross R, Yenni R, Elliott D, Rouelle J . Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun. 2016; 7:11544. PMC: 4866400. DOI: 10.1038/ncomms11544. View

Wiley M, Fakoli L, Letizia A, Welch S, Ladner J, Prieto K . Lassa virus circulating in Liberia: a retrospective genomic characterisation. Lancet Infect Dis. 2019; 19(12):1371-1378. DOI: 10.1016/S1473-3099(19)30486-4. View

10.

Boisen M, Hartnett J, Shaffer J, Goba A, Momoh M, Sandi J . Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep. 2018; 8(1):5939. PMC: 5897328. DOI: 10.1038/s41598-018-24246-w. View

11.

Matranga C, Gladden-Young A, Qu J, Winnicki S, Nosamiefan D, Levin J . Unbiased Deep Sequencing of RNA Viruses from Clinical Samples. J Vis Exp. 2016; (113). PMC: 4993327. DOI: 10.3791/54117. View

12.

Barnes K, Lachenauer A, Nitido A, Siddiqui S, Gross R, Beitzel B . Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. Nat Commun. 2020; 11(1):4131. PMC: 7431545. DOI: 10.1038/s41467-020-17994-9. View

13.

Bernasconi V, Kristiansen P, Whelan M, Roman R, Bettis A, Yimer S . Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019; 63(1):65-73. PMC: 6925075. DOI: 10.1007/s00103-019-03061-2. View

14.

Madu I, Files M, Gharaibeh D, Moore A, Jung K, Gowen B . A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018; 14(12):e1007439. PMC: 6322784. DOI: 10.1371/journal.ppat.1007439. View

15.

Mazzola L, Kelly-Cirino C . Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings. BMJ Glob Health. 2019; 4(Suppl 2):e001116. PMC: 6407561. DOI: 10.1136/bmjgh-2018-001116. View

16.

Bausch D, Demby A, Coulibaly M, Kanu J, Goba A, Bah A . Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis. 2003; 1(4):269-81. DOI: 10.1089/15303660160025903. View

17.

Grove J, Branco L, Boisen M, Muncy I, Henderson L, Schieffellin J . Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J. 2011; 8:314. PMC: 3283910. DOI: 10.1186/1743-422X-8-314. View

18.

Walker D, McCormick J, Johnson K, WEBB P, ELLIOTT L, Gardner J . Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol. 1982; 107(3):349-56. PMC: 1916239. View

19.

Wulff H, Lange J . Indirect immunofluorescence for the diagnosis of Lassa fever infection. Bull World Health Organ. 1975; 52(4-6):429-36. PMC: 2366649. View

20.

Grabherr M, Haas B, Yassour M, Levin J, Thompson D, Amit I . Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat Biotechnol. 2011; 29(7):644-52. PMC: 3571712. DOI: 10.1038/nbt.1883. View